Global Parkinson's Disease Market Expected to Achieve 8.1% CAGR by 2029: Growth Forecast Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Parkinson's Disease Market Size By 2025?
The market for treating Parkinson's disease has experienced significant expansion lately; its valuation is projected to climb from three point thirty-four billion dollars in 2024 to three point sixty-two billion dollars the following year, reflecting an eight point two percent compound annual growth rate. This upward trajectory during the past period is largely due to escalated investment in R&D endeavors, bolstered governmental financial backing, the proliferation of tailored therapeutic strategies, the expansion of peer and institutional support systems established for those afflicted with Parkinson's, and the wider adoption of sophisticated physical recovery methods.

How Big Is the Parkinson's Disease Market Size Expected to Grow by 2029?
Anticipating robust expansion in the forthcoming years, the market specifically addressing parkinson's disease is projected to attain a valuation of $4.94 billion by 2029, driven by a compound annual growth rate (CAGR) equating to 8.1%. This upswing throughout the projection timeframe is fundamentally linked to several factors: heightened societal recognition regarding the indicators of parkinson's disease, escalating support through governmental programs, increased expenditures within the healthcare sector, a greater volume of ongoing clinical investigations for Parkinson's disease, and the increasing implementation of gene-based treatments. Key developments shaping this period encompass breakthroughs in technology, increased governmental engagement and financial backing, the integration of artificial intelligence for diagnostic purposes, development of novel treatment approaches, and a shift towards individualized patient care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Which Key Market Drivers Powering Parkinson's Disease Market Expansion and Growth?
The escalating incidence of conditions affecting the nervous system is anticipated to boost the expansion of the market for Parkinson's disease in the future, as neurodegenerative disorders, defined by the gradual deterioration and functional depletion of brain and nervous system neurons, are becoming more common due to an aging populace, genetic susceptibilities, external factors, better diagnostic capabilities, an increase in persistent health issues, and shifts in lifestyle; furthermore, Parkinson's disease contributes significantly to advancing knowledge regarding these neurodegenerative conditions by illuminating their base mechanisms, identifying promising treatment avenues, and facilitating the creation of novel therapies; as an illustration, the European Brain Council, headquartered in Belgium, reported in April 2022 that more than 600 nervous system diseases and close to 300 mental health disorders affect large numbers worldwide, including 65 million individuals with epilepsy, and within Europe specifically, the number of people suffering from dementia currently stands at 10.5 million, with forecasts suggesting this figure will climb to 18.7 million by the middle of the century, consequently underpinning the market expansion in the Parkinson's disease sector through the heightened frequency of neurodegenerative illnesses.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Parkinson's Disease Market?
Leading corporations within the Parkinson's disease sector are concentrating efforts on bringing forth novel therapeutic approaches, notably those centered on levodopa, with the objective of enhancing afflicted patients' motor capabilities and ensuring uninterrupted symptom control, especially for those in advanced stages of the condition.This therapeutic strategy involving levodopa functions by administering a substance that the brain transforms into dopamine, thereby boosting motor performance and lessening the manifestation of Parkinson's symptoms.Significantly, in October 2024, the US regulatory body, the Food and Drug Administration (FDA), authorized VYALEV, a dual-drug treatment combining levodopa and carbidopa, developed by the American biopharmaceutical firm AbbVie Inc. for addressing Parkinson's disease.The composition of this particular agent is engineered to heighten levodopa's effectiveness by preventing its premature degradation prior to reaching its target in the brain, consequently elevating dopamine concentrations.This pharmaceutical agent proves beneficial in controlling the physical manifestations of Parkinson's, such as shaking, stiffness, and slowness of movement, leading to an improvement in the patient's capacity to perform routine activities, and it stands out as a primary treatment option for individuals grappling with intermittent movement problems associated with Parkinson's disease.

What Are the Emerging Segments in the Parkinson's Disease Market?
The parkinson's diseasemarket covered in this report is segmented -

1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes
2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
4) By Patient Care Setting: Clinics; Hospitals

Subsegments:
1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives
2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone
3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide
4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine
5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations
6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21247&type=smp

Who Are the Global Leaders in the Parkinson's Disease Market?
Major companies operating in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

Which are the Top Profitable Regional Markets for the Parkinson's Disease Industry?
North America was the largest region in the parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21247

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.